Fusidic acid, licensed for some decades outside the US and is in clinical development in the U.S.
•
Jan 2010: Taksta has completed enrollment in a Phase 2 trial (due to run until March 2010) and is preparing for Phase 3 studies in the U.S. for acute bacterial skin structure infections (being compared with Linezolid).